TURNOVER (x1000 SEK)
NET PROFIT (x1000 SEK)
Polypeptide Laboratories Holding (PPL) AB
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,812,711
|
1,733,805
|
1,325,018 |
| Financial expenses |
183,630
|
125,451
|
43,574 |
| Earnings before taxes |
-347,024
|
-332,114
|
-211,748 |
| EBITDA |
-283,140
|
-571,055
|
-167,751 |
| Total assets |
4,876,652
|
4,385,450
|
2,993,944 |
| Current assets |
1,331,055
|
1,496,473
|
580,658 |
| Current liabilities |
2,090,099
|
1,309,339
|
849,961 |
| Equity capital |
325,688
|
414,336
|
547,704 |
| - share capital |
206
|
200
|
200 |
| Employees (average) |
0
|
0
|
0 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
6.7%
|
9.4%
|
18.3% |
| Turnover per employee | |||
| Profit as a percentage of turnover |
-19.1%
|
-19.2%
|
-16.0% |
| Return on assets (ROA) |
-3.4%
|
-4.7%
|
-5.6% |
| Current ratio |
63.7%
|
114.3%
|
68.3% |
| Return on equity (ROE) |
-106.6%
|
-80.2%
|
-38.7% |
| Change turnover |
78,906
|
408,787
|
432,842 |
| Change turnover % |
5%
|
31%
|
49% |
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.